<DOC>
	<DOCNO>NCT02491970</DOCNO>
	<brief_summary>The purpose study demonstrate superiority Fluticasone/Formoterol ( Flutiform® ) Fluticasone/salmeterol base small airway function assess Impulse Oscillometic System ( IOS ) uncontrolled asthma patient require ICS/LABA concomitant treatment .</brief_summary>
	<brief_title>Study Evaluate Small Airway Parameters Fluticasone/Formoterol ( Flutiform® ) Compared Fluticasone/Salmeterol Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>1 . Adult ( 19 year ) asthma patient 2 . Patients history mildtomoderatesevere , persistent asthma least 6 month prior Screening . 3 . Patients required demonstrate FEV1 ≥ 40 % ≤ 85 % predict normal value screen period follow appropriate withhold asthma medication ( applicable ) . 4 . Patients require show reversibility ≥15 % FEV1 salbutamol inhalation ( 2 actuation , 100µg per actuation ) pre salbutamol value screen 5 . Patients uncontrolled asthma Seretide® 250/50 define ACT le 20 6 . Patients show R520 0.1 kPa/L/s 7 . Blood eosinophil count &gt; 300/µL screen visit 8 . Female patient childbearing potential must negative urine pregnancy test Screening . 9 . Patients able use inhaler 10 . Patients willing voluntarily sign study consent form 1 . Patients experience lifethreatening asthma within 12 month prior screen respiratory infection within 4 week prior screen , patient experience emergency visit hospitalization due acute asthma symptom within 4 week prior screen 2 . Patients diagnose clinically significant disease non reversible pulmonary disease patient currently active pulmonary disease ( eg . COPD , cystic fibrosis , bronchiectasis , active tuberculosis ) 3 . Patients diagnose laryngitis , chronic sinusitis , infectious rhinitis allergic rhinitis within 4 week prior screen , patient symptoms acute exacerbation purulent discharge disease within 2 week prior screen 4 . Current smoker past smoker define : Current smoker : smoking history within 12 month prior screen Past smoker : smoking amount ≥10 pack year* Pack year ( PY ) calculation : average amount smoke per day ( pack ) x duration smoking ( year ) 5 . Patients currently pregnant lactate 6 . Patient take systemic corticosteroid within 4 week prior screen 7 . Patients take omalizumab within 24 week prior screen 8 . Patients take follow medication within 1 week prior screening : potent CYP3A inhibitor βblockers monoamine oxidase inhibitor TCA ( tricyclic antidepressant ) quinidinetype anti arrhythmic Leukotriene anatagonist Astemizole 9 . Patients participate go participate interventional clinical trial 10 . QT interval prolongation ECG result screen 11 . Patients hypersensitive investigational product component drug 12 . Patients judge difficult participate investigation investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>